Who we are
Learn about our history and how our organization helps the Canadian Alpha-1 community.
AlphaNet Canada is a registered charity and national patient organization committed to improving the lives of individuals in Canada affected by alpha-1 antitrypsin deficiency.
In 2024, Canada became the first country globally to provide an Alpha-1 proteinase inhibitor through a national blood operator for severely affected Alpha-1 patients requiring treatment. This milestone unified the Canadian Alpha-1 community like never before, leading to the merger of Alpha-1 Canada and AlphaNet Canada.
Both organizations had been active advocates in the Canadian rare disease space for over a decade. Together, they look forward to strengthening and broadening the services provided to the Canadian Alpha-1 community under the AlphaNet Canada name.
The AlphaNet Disease Management and Prevention program, commonly known as the ADMAP program, underpins the effort to improve the quality of life of Canadian Alphas. This program has resulted in high augmentation therapy compliance with fewer exacerbations, unscheduled doctor visits, and hospitalizations.
